Biotech Specialty Pharma

Synthetic Biologics, Inc.

155 Gibbs Street, Ste. 412
Rockville, MD 20850 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Biologics for the prevention/treatment of serious infectious and other diseases.

Management Jeffrey Riley, CEO, President and Director; Evan Ballantyne, CFO; John Monahan, PhD, EVP, Research & Development; Carol Reed, MD, SVP, Clinical & Regulatory; Michael Kaleko, MD, PhD, SVP, Research & Development; Lew Barrett, SVP, Commercial Strategy

Click here for Financial Data
Keywords: infectious diseases, C. difficile, pertussis, Acinetobacter, multiple sclerosis, synthetic biologics, monoclonal antibodies, estriol, beta-lactamase oral enzyme, ibs, Intrexon


Updated: Oct. 22, 2015


Biotechnology company focused on the development of biologics for prevention and treatment of serious infectious and other diseases.The company is developing an oral enzyme for the prevention of C. di......view more

Products / Services

1) Multiple Sclerosis - Trimesta (oral estriol) is in a Phase II clinical trial being evaluated for the treatment of relapsing-remitting multiple sclerosis. 2) Archaea-associated diseases (C-IBS,......view more

Technology / Differentiation

Trimesta (oral estriol) is an investigational oral drug being developed for the treatment of relapses in multiple sclerosis (MS) and cognitive dysfunction in MS. Estriol has been approved and marketed...view more

Market / Customers

Serious infectious diseases......view more

Analyst Coverage